Aphria Inc (NYSE:APHA) Expected to Announce Quarterly Sales of $99.49 Million

Brokerages predict that Aphria Inc (NYSE:APHA) will announce sales of $99.49 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aphria’s earnings, with estimates ranging from $94.85 million to $104.13 million. Aphria reported sales of $96.12 million in the same quarter last year, which would suggest a positive year over year growth rate of 3.5%. The business is scheduled to issue its next earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Aphria will report full-year sales of $383.65 million for the current financial year, with estimates ranging from $372.02 million to $402.93 million. For the next fiscal year, analysts expect that the company will post sales of $504.92 million, with estimates ranging from $432.26 million to $576.11 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Aphria.

Aphria (NYSE:APHA) last announced its earnings results on Tuesday, April 14th. The company reported $0.02 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.06. The business had revenue of $144.40 million during the quarter, compared to the consensus estimate of $130.74 million. Aphria had a net margin of 5.75% and a negative return on equity of 0.30%. The firm’s revenue was up 96.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) earnings per share.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Aphria from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Bank of America upped their target price on Aphria from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Stifel Nicolaus upped their target price on Aphria from $4.50 to $5.30 and gave the company a “hold” rating in a research report on Thursday, April 16th. Eight Capital upgraded Aphria to a “buy” rating in a research report on Thursday, April 16th. Finally, Alliance Global Partners reiterated a “buy” rating and issued a $9.00 target price (down previously from $11.00) on shares of Aphria in a research report on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Aphria currently has a consensus rating of “Buy” and a consensus target price of $7.71.

Several hedge funds have recently made changes to their positions in APHA. Cambridge Investment Research Advisors Inc. raised its stake in shares of Aphria by 12.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 41,728 shares of the company’s stock worth $218,000 after buying an additional 4,678 shares during the period. Swiss National Bank raised its stake in Aphria by 1.5% in the 4th quarter. Swiss National Bank now owns 458,100 shares of the company’s stock valued at $2,389,000 after purchasing an additional 6,800 shares during the last quarter. Private Advisor Group LLC raised its stake in Aphria by 104.8% in the 4th quarter. Private Advisor Group LLC now owns 49,155 shares of the company’s stock valued at $232,000 after purchasing an additional 25,152 shares during the last quarter. Cannell Peter B & Co. Inc. raised its stake in Aphria by 13.6% in the 4th quarter. Cannell Peter B & Co. Inc. now owns 25,550 shares of the company’s stock valued at $133,000 after purchasing an additional 3,050 shares during the last quarter. Finally, Moser Wealth Advisors LLC acquired a new position in Aphria in the 4th quarter valued at $52,000. 9.57% of the stock is owned by institutional investors and hedge funds.

Shares of APHA stock traded down $0.16 during trading hours on Monday, reaching $4.07. 3,460,600 shares of the company’s stock were exchanged, compared to its average volume of 6,526,876. Aphria has a 1 year low of $1.95 and a 1 year high of $7.60. The stock has a market cap of $1.16 billion, a PE ratio of 47.44 and a beta of 2.19. The company has a current ratio of 5.19, a quick ratio of 3.73 and a debt-to-equity ratio of 0.25. The stock’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $4.06.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

See Also: 12b-1 Fees

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.